Mysoline Related Published Studies
Well-designed clinical trials related to Mysoline (Primidone)
Comparison of add-on valproate and primidone in carbamazepine-unresponsive patients with partial epilepsy. [2009.03]
Use of primidone in low doses (250 mg/day) versus high doses (750 mg/day) in the management of essential tremor. Double-blind comparative study with one-year follow-up. [2003.10]
Randomized trial comparing primidone initiation schedules for treating essential tremor. [2002.03]
Lack of in vivo/in vitro correlations for 50 mg and 250 mg primidone tablets. [1998.07]
Well-designed clinical trials possibly related to Mysoline (Primidone)
What did STAR*D teach us? Results from a large-scale, practical, clinical trial for patients with depression. [2009.11]
Rapid and simultaneous determination of sulfamethoxazole and trimethoprim in human plasma by high-performance liquid chromatography. [2007.02.19]
[Hyperhomocysteinemia and treatment with antiepileptic drugs. Effects of different doses of folic acid] [2005.04.16]
Effect of levetiracetam on the pharmacokinetics of adjunctive antiepileptic drugs: a pooled analysis of data from randomized clinical trials. [2005.03]
Pilot efficacy and tolerability: a randomized, placebo-controlled trial of levetiracetam for essential tremor. [2004.10]
Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. [2003.02]
Clinical and electromyographic assessment of essential tremor treatment. [2002.06]
New alternative agents in essential tremor therapy: double-blind placebo-controlled study of alprazolam and acetazolamide. [2000.10]
A multicenter randomized controlled trial on the clinical impact of therapeutic drug monitoring in patients with newly diagnosed epilepsy. The Italian TDM Study Group in Epilepsy. [2000.02]
Does withdrawal of different antiepileptic drugs have different effects on seizure recurrence? Further results from the MRC Antiepileptic Drug Withdrawal Study. [1999.03]
Effectiveness of piracetam in cortical myoclonus. [1993]
Quantitative comparison of barbiturates in essential hand and head tremor. [1991]
Other research related to Mysoline (Primidone)
Comparison of add-on valproate and primidone in carbamazepine-unresponsive patients with partial epilepsy. [2008.07.29]
Is primidone the drug of choice for epileptic patients with QT-prolongation? A comprehensive analysis of literature. [2006.01]
Primidone is associated with interictal depression in patients with epilepsy. [2005.05]
[Antiepileptic primidone shortly to be withdrawn from sale: change medication now] [2003.11.22]
Primidone-induced hyperammonemic encephalopathy in a patient with cerebral astrocytoma. [2002.01]
Effects of encapsulation of primidone on its oxidative metabolism in rats. [2001]
The "forgotten" cross-tolerance between phenobarbital and primidone: it can prevent acute primidone-related toxicity. [2000.10]
The use of primidone in the treatment of refractory bipolar disorder. [1999.06]
Systematic testing of medical intractability for carbamazepine, phenytoin, and phenobarbital or primidone in monotherapy for patients considered for epilepsy surgery. [1996.07]
Clinical pharmacokinetics of antiepileptic drugs in paediatric patients. Part I: Phenobarbital, primidone, valproic acid, ethosuximide and mesuximide. [1995.10]
Other possibly related research studies
[Zonisamide in refractory essential tremor] [2008.02.01]
Mitochondrial complex I encephalomyopathy and cerebral 5-methyltetrahydrofolate deficiency. [2007.08]
[Therapeutical strategies for essential tremor] [2007.11.03]
Antiepileptic drug use, folic acid supplementation, and congenital abnormalities: a population-based case-control study. [2008.01]
Inhibition of human aromatase complex (CYP19) by antiepileptic drugs. [2008.02]
Phenobarbital-induced gingival hyperplasia. [2007.09.01]
[Diagnosis and treatment of tremor in Parkinson's disease and essential tremor] [2007.05.21]
[Rational combination therapy in epilepsy. II. Clinical and pharmacological aspects] [2007.08.01]
[Effectiveness and safety of levetiracetam in patients with essential tremor: data from an open 11-week follow-up trial.] [2007.08.01]
[Antiepileptic drug-induced osteopathy. Subtypes, pathogenesis, prevention, early diagnosis and treatment] [2007.07.29]
Transient improvement of essential tremor during electroconvulsive therapy. [2007.06]
[Deep brain stimulation of the ventral intermediate thalamic nucleus in the treatment of essential tremor] [2007.03]
Comparison and predictors of rash associated with 15 antiepileptic drugs. [2007.05.15]
Therapeutic monitoring of antiepileptic drugs for epilepsy. [2007.01.24]
[Tremor] [2007.01]
Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. [2006.12]
Epilepsy and the impact of an epileptology clinic for patients with mental retardation and associated disabilities in an institutional setting. [2006.12]
Anticonvulsant hypersensitivity syndrome: cross-reactivity with tricyclic antidepressant agents. [2006.11]
Differences between prescribed daily doses and defined daily doses of antiepileptics--therapeutic drug monitoring as a marker of the quality of the treatment. [2006.09]
Oxcarbazepine use in essential tremor. [2006.10]
CYP2C19 polymorphism and risk for essential tremor. [2006]
Phenytoin desensitization in a child with symptomatic localization-related epilepsy. [2007.03]
Essential tremor-the most common movement disorder in older people. [2006.07]
[Carbamazepine-induced systemic lupus erythematosus--a case report] [2006.03]
Management of epilepsy and pregnancy. [2006.01]
Lack of interactions between breast cancer resistance protein (bcrp/abcg2) and selected antiepileptic agents. [2006.03]
Nonparkinsonism movement disorders in the elderly. [2006.01]
Clinically relevant drug interactions with antiepileptic drugs. [2006.03]
[Generic drugs in the treatment of epilepsy] [2005.12.01]
Alteration of thyroid hormone homeostasis by antiepileptic drugs in humans: involvement of glucuronosyltransferase induction. [2005.12]
Rhythmic EMG and EEG activity during voluntary movement in posthypoxic cortical action myoclonus. [2005.09.01]
Benefits and risks of pharmacological and surgical treatments for essential tremor: disease mechanisms and current management. [2005.09]
Dose-dependent apoptotic and necrotic myocyte death induced by the beta2-adrenergic receptor agonist, clenbuterol. [2005.12]
Practice parameter: therapies for essential tremor: report of the Quality Standards Subcommittee of the American Academy of Neurology. [2005.06.28]
Anticonvulsant activity and tolerance of ELB138 in dogs with epilepsy: a clinical pilot study. [2006.07]
Determination of levetiracetam in human plasma with minimal sample pretreatment. [2005.05.05]
Pharmacological treatment of disabling tremor. [2005.03]
Genetic essential tremor in gamma-aminobutyric acidA receptor alpha1 subunit knockout mice. [2005.03]
Drug-induced hypersensitivity syndrome in a premature infant. [2005.01]
When breastfeeding mothers need CNS-acting drugs. [2004.09]
Initial treatment of epilepsy: special issues in treating the elderly. [2004.11.23]
Fracture risk associated with use of antiepileptic drugs. [2004.11]
Anticonvulsant efficacy of the low-affinity partial benzodiazepine receptor agonist ELB 138 in a dog seizure model and in epileptic dogs with spontaneously recurrent seizures. [2004.10]
Efficacy and tolerability of the new antiepileptic drugs: comparison of two recent guidelines. [2004.10]
Essential tremor. Epidemiology, diagnosis, and treatment. [2004.09]
Epilepsy in the United Kingdom: seizure frequency and severity, anti-epileptic drug utilization and impact on life in 1652 people with epilepsy. [2004.09]
Spectrum of epilepsy in tuberous sclerosis. [2004.06]
Natural history and syndromic associations of orthostatic tremor: a review of 41 patients. [2004.07]
Antiepileptic drugs: indications other than epilepsy. [2004.06]
Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. [2004.07]
Epilepsy and bone health in adults. [2004.02]
[Drug interactions with antiepileptic agents] [2004.02.28]
Low doses of topiramate are effective in essential tremor: a report of three cases. [2003.11]
[Oxcarbazepine induced interstitial nephritis in a patient with drug hypersensitivity syndrome] [2003.11.16]
Essential tremor: diagnosis and treatment. [2003.09]
Antiepileptic drug pharmacokinetics during pregnancy and lactation. [2003.09.01]
The ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? [2003.05]
Essential tremor: differential diagnosis and current therapy. [2003.08.01]
Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. [2003.08]
Tremor. [2003.08]
Clinically important drug interactions in epilepsy: general features and interactions between antiepileptic drugs. [2003.06]
Benefits and risks of pharmacological treatments for essential tremor. [2003]
Tremor--easily seen but difficult to describe and treat. [2003.03]
Effects of concomitant antiepileptic drugs on serum carbamazepine concentration in epileptic patients: quantitative analysis based on extracellular water volume as a transforming factor. [2003.01]
Drug treatment of epilepsy in elderly people: focus on valproic Acid. [2003]
Prolonged anticonvulsant hypersensitivity syndrome related to lamotrigine in a patient with human immunodeficiency virus. [2002.11]
The absorption of gabapentin following high dose escalation. [2003.01]
Primary standardization of assays for anticonvulsant drugs: comparison of accuracy and precision. [2002.11]
Some common issues in the use of antiepileptic drugs. [2002.03]
Treatment of epilepsy in women of reproductive age: pharmacokinetic considerations. [2002]
Management of essential tremor. [2002.07]
Serum concentrations of topiramate in patients with epilepsy: influence of dose, age, and comedication. [2002.06]
Effect of antiepileptic drugs on bone density in ambulatory patients. [2002.05.14]
[Evaluation of antiepileptic therapy during pregnancy] [2002.01]
Anticonvulsant hypersensitivity syndrome. [2002.03]
|
